Medtronic plc. (MDT) Shares Bought by Corient Capital Partners LLC
Corient Capital Partners LLC raised its holdings in shares of Medtronic plc. (NYSE:MDT) by 9.9% in the fourth quarter, Holdings Channel reports. The institutional investor owned 18,714 shares of the medical technology company’s stock after buying an additional 1,685 shares during the quarter. Corient Capital Partners LLC’s holdings in Medtronic were worth $1,512,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds have also modified their holdings of the company. 180 Wealth Advisors LLC acquired a new position in shares of Medtronic during the fourth quarter worth approximately $566,000. Pittenger & Anderson Inc. raised its stake in shares of Medtronic by 9.5% in the fourth quarter. Pittenger & Anderson Inc. now owns 27,162 shares of the medical technology company’s stock valued at $2,193,000 after purchasing an additional 2,367 shares in the last quarter. WINTON GROUP Ltd raised its stake in shares of Medtronic by 340.0% in the fourth quarter. WINTON GROUP Ltd now owns 77,164 shares of the medical technology company’s stock valued at $6,231,000 after purchasing an additional 59,625 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Medtronic by 2.5% in the fourth quarter. Geode Capital Management LLC now owns 14,191,675 shares of the medical technology company’s stock valued at $1,143,549,000 after purchasing an additional 351,256 shares in the last quarter. Finally, Sequoia Financial Advisors LLC raised its stake in shares of Medtronic by 20.6% in the fourth quarter. Sequoia Financial Advisors LLC now owns 6,566 shares of the medical technology company’s stock valued at $530,000 after purchasing an additional 1,120 shares in the last quarter. Institutional investors own 79.89% of the company’s stock.
Medtronic plc. (MDT) opened at $78.33 on Monday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 2.09 and a current ratio of 2.43. Medtronic plc. has a 12 month low of $76.51 and a 12 month high of $89.72. The stock has a market capitalization of $106,166.38, a price-to-earnings ratio of 16.70, a price-to-earnings-growth ratio of 2.22 and a beta of 0.97.
A number of brokerages recently commented on MDT. Citigroup restated a “buy” rating and issued a $93.00 target price (down from $100.00) on shares of Medtronic in a research note on Thursday, February 22nd. TheStreet lowered Medtronic from a “b” rating to a “c+” rating in a research note on Tuesday, February 20th. Oppenheimer restated a “buy” rating and issued a $94.00 target price on shares of Medtronic in a research note on Tuesday, February 20th. Royal Bank of Canada restated an “outperform” rating and issued a $92.00 target price on shares of Medtronic in a research note on Wednesday, February 14th. Finally, Morgan Stanley upped their target price on Medtronic from $91.00 to $95.00 and gave the company an “equal weight” rating in a research note on Monday, February 5th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and sixteen have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $91.50.
In other news, EVP Hooman Hakami sold 26,158 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $85.00, for a total transaction of $2,223,430.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Bryan C. Hanson sold 16,000 shares of the stock in a transaction on Friday, December 15th. The stock was sold at an average price of $82.82, for a total value of $1,325,120.00. Following the sale, the executive vice president now owns 88,818 shares in the company, valued at approximately $7,355,906.76. The disclosure for this sale can be found here. Insiders have sold 120,684 shares of company stock worth $10,318,276 in the last 90 days. Company insiders own 0.31% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Medtronic plc. (MDT) Shares Bought by Corient Capital Partners LLC” was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this story on another domain, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The correct version of this story can be accessed at https://www.dailypolitical.com/2018/03/05/medtronic-plc-mdt-shares-bought-by-corient-capital-partners-llc.html.
Medtronic Public Limited Company (Medtronic) is a medical technology and services company. The Company develops, manufactures and markets its medical devices and technologies to hospitals, physicians, clinicians and patients in approximately 160 countries. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Technologies Group, Restorative Therapies Group and Diabetes Group.
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc. (NYSE:MDT).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.